contents

INTRODUCTION --------------------------------- PAGE 2

SWOT ---------------------------------- PAGE 3

BUSINESS MODEL ---------------------------------- PAGE 6

CORE COMPETENCY ---------------------------------- PAGE 6

FUTURE STRATEGY ---------------------------------- PAGE 7

Introduction

Claris lifesciences is an IPR driven ,Ahmadabad based international pharmaceutical

company , in the business of manufacturing and marketing of high end injectables with
focus on new drug delivery system for treatment of critical illness and diseases.

With emphasis on quality, technology & innovation, Claris offers a range of niche
technology aqueous & lipid emulsion injectable products across delivery system such as
bottles, vials, ampoules, non-PVC/PVC bags.

VISION

To be one of the world`s leading and most admired pharmaceutical companies in the
global generics industry.

To continually create value and bring pride to our stakeholders, partners, customer and
the community at large.

To preserve earth`s most precious resource……..human lives.

MISSION

A world class organization, built on,

• Outstanding performance led by entrepreneurial culture.

• Product quality through emotional pharmacopoeia
• Management capability, efficient processes and technology.
• Youth, hard work and discipline.

Achieved in a manner of fairness, honesty and corporate responsibility.

STRENGTHS

• Advantage of being in the injectable segment: Claris focus on the higher value
added injectables market, which has more stable margins, lower price
competition and less susceptibility to raw material price fluctuations as compared
to other generic segments.
• USPs: Claris has cGMP and ISO9001:2000 certified facilities. Sterile parentral
preparation manufacturing facilities approved by international regulatory
authorities like
USFDA,MHRA(UK),TGA(AUSTRALIA),NAM(FINLAND),GCC(GULF),ANVISA(B
RAZIL). Company has an expertise in injectable manufacture. Claris hold a
process patent in India for manufacturing pyrogen free hydroxyethyl starch (API).
• Resources: 5 manufacturing units, complete in house analytical facility, quality
equipments mainly sourced from Europe, well trained workforce of 2000
employees. A team of more than 100 research scientists engaged in R&D.
• Market reach and distribution: established subsidiaries named Claris life sciences
limited in USA,UK and AUSTRALIA. Distribution network in more than 76
countries. Marketing tie up with pharma giant PFIZER for marketing in the west.
Company has over one lakh distributors all over the world.
• Innovation: company has Claris research foundation whose focus area is
development of innovative products and NDDS. Company also has a venture
Xcelris labs dedicated to gain excellence in the drug development process and
(CRAMS) contract research and manufacturing, Xcelris has already various
research projects in hand from USA and UK.
• Growth: Claris achieved a record 44% growth, has filed 18 ANDAs in the US
and submitted 2000+ dossiers to various countries for market authorization.
• Certification and accolades: apart from certification by regulatory authorities
Claris have won IDMA award thrice for quality practice, IMEA award for two
consecutive years and first position in international supply chain category at
Gujarat logistics award.
• Culture, attitude and philosophy: achieved oriented, value and merit based work
culture. Quality philosophy is to match highest international pharmacopeal
 standards. Company practice emotional pharmacopeia which says that ask a
simple question about quality of your product, “would you use your product to
treat your dearest one?”
• Company has huge sale force which also provide after sales services.
• Only Indian company to have biomass co-generation facility(CDM project
no.1852) showing the way forward for a solution to climate change.
• Company has no liability arising from earlier venture core healthcare ltd.

WEAKNESS

• Focus area can limit the company growth because company`s focus area is only
generic injectable market which is only 35% of total generic market and injectable
market is further only 19% of total pharma market.(data according to 2008-09
figures by McKinsey & company)
• Company is still a toddler, manufacturing facilities have started only in 2002 and
company lacks established track records.
• In total injectable industry growth is expected only from existing generics and no
new molecule is expected in near future.
• Cash and capital: company does not have huge cash reserves to finance all its
expansion programmes and option left for company is debt or IPO.
• According to CEO of Company, company is needed to have systems-and-
process –oriented professional approach rather than the existing entrepreneurial
and personalized approach.
• Management depth and breadth is needed.

OPPORTUNITIES
 • Market development: for claris generic market is developing, threat of
competition is always there but still in India generic injectable market is growing
at 13.7% and there is demand of generics from governments across the world to
keep healthcare budget under control. Also due to rise in public spending in
health, greater private involvement, corporate hospitals and growth in private
health insurance there is opportunity of increasing the market share.
• Claris can sees soon to be off patented injectable as an opportunity to increase
its product basket.
• Oncology and diabetes are the two therapeutic segment in which company is
planning to formulate injectables.
• As company has expertise in sterile preparations Claris can manufacture
vaccines, steroids and biotechnological products because they share same
technology, production facility and R&D as by sterile preparations.
• As company has network in over 80 countries company cal search further new
semi regulated markets to expand its business. Claris hasn`t started its business
in China, Japan and Indonesia.
• Company has option to target niche segment in foreign countries through
strategic alliance and merger.
• IPO for raising money because company yet has not yet offered IPO.
• Branding and creating brand equity.

THREATS

• Regulations: regulated markets offer lot of hindrance in operations and time

consuming procedures to give access to market.
• Global financial downturn and economic crisis pose threat to business.
• China is emerging as a big competitor is generic business.
• Multinationals competing with Claris such as Baxter has huge capitals to fund
their operations unlike Claris and thus they can limit its business.
 • Due to paced industry growth lot of more competitors like Sandoz, Orchid,strides
acrolabs , Fresenius kabi and giants like Sun pharma , Zudus Cadila, Wockhardt
also have intentions in generic injectable business.
• Bigger giants are looking for partnering and acquisitions and also bigger
multinationals offer great completion in product performance, technological
innovation and service.
• Due to its expansion plans in future, company needs workforce of new 800
employees and company is facing shortage of skilled manpower in Gujarat.

BUSINESS MODEL

Company operates on two different business models, one for domestic Indian market
and second for international market.

In India company has huge saleforce, own manufacturing facilities, sales and marketing
department and is playing a volume based game.Claris in India is selling and
distributing its products under its own name.

In foreign countries Claris is having distributor based model by setting up its own
subsidraies and joining with generics players of respective markets.in Australia Claris
recently tied up with Mayne pharma and had initiated supply of its global brand Provive
for its distribution in Australia and New Zealand. And same model is practiced in other
parts of global market.

Core competency

Company enjoys core competency in

• New drug delivery systems for treatment of critical illness

• High end life saving injectables
• Expertise in injectables technology, manufacturing and R&D
• Cost-competitiveness

Claris`s earlier venture core healthcare also had expertise in injectables.

However company has a huge product basket catering to the following therapeutic
segments

Parenteral nutrition--------------- TNA/TNA-peri

Enteral nutrition--------------------- glutammune

Anasethesia ------------------------- provive

Blood products------------------------hestar

Anti-infectives----------------------------ceftrion

Renal care-------------------------------- limus

FUTURE STRATEGY

Enter into new therapeutic segment of pain management and oncology.

Enter into new market like Russia, China, Japan and Turkey.

Enter into niche area of a therapeutic segment that attracts less competition.

Manufacture of vaccines and biotechnological products.

Look for IPO to finance its biotechnology and oncology operations which need about
INR 3.5 billion.